Search results
Results from the WOW.Com Content Network
See the list of FDA-approved therapeutic monoclonal antibodies in the monoclonal antibody therapy page. This is a dynamic list and may never be able to satisfy particular standards for completeness. You can help by adding missing items with reliable sources .
Its name is composed of the components olara-t-u-mab. This shows that the drug is a human monoclonal antibody acting against tumors. [34] The name of benralizumab, a drug designed for the treatment of asthma, has the components benra-li-zu-mab, marking it as a humanized antibody acting on the immune system. [42]
Pages in category "Drugs that are a monoclonal antibody" The following 200 pages are in this category, out of approximately 482 total. This list may not reflect recent changes .
Osteoporosis, including drug- and cancer-related osteoporosis, giant cell tumour of bone and hypercalcaemia of malignancies: Hypercholesterolaemia, cataract, urinary retention, hypocalcaemia, osteonecrosis of the jaw and anaphylaxis. Gemtuzumab ozogamicin: IV: CD33 antibody that induces apoptosis of the tagged cell. Acute myeloid leukaemia
The first FDA-approved therapeutic monoclonal antibody was a murine IgG2a CD3 specific transplant rejection drug, OKT3 (also called muromonab), in 1986. This drug found use in solid organ transplant recipients who became steroid resistant. [39] Hundreds of therapies are undergoing clinical trials. Most are concerned with immunological and ...
Leqembi, known generically as lecanemab, is a monoclonal antibody that works to remove a protein called amyloid from the brain. It received full Food and Drug Administration approval in July.
Drug nomenclature is the systematic naming of drugs, especially pharmaceutical drugs.In the majority of circumstances, drugs have 3 types of names: chemical names, the most important of which is the IUPAC name; generic or nonproprietary names, the most important of which are international nonproprietary names (INNs); and trade names, which are brand names. [1]
The deal termination will be effective Nov. 20 this year, and will not affect upfront and milestone payments of $200 million that the company has received from AbbVie, according to I-Mab. I-Mab ...